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The well-known anti-inflammatory properties of the natural glucocorticoid cortisol, has led to 
the development of synthetic glucocorticoid analogues, which exert even higher anti-
inflammatory activities. Beside the anti-inflammatory properties, these drugs also induce 
body weight gain in production animals by improving feed intake and lowering feed 
conversion. Due to their growth-promoting effects, the use of synthetic glucocorticoids is 
strictly regulated in the European Union (Council Directive 2003/74/EC). In the frame of the 
national control plans, which should ensure the absence of residues in food products of animal 
origin, in recent years, a higher frequency of prednisolone positive bovine urines has been 
observed. In an attempt to understand the origin of this prednisolone, an in-vivo study was 
conducted on adult Holstein-Friesian cows for further deepening of the knowledge about the 
metabolism and distribution of prednisolone in cattle intended for meat production and to 
allow the characterisation of metabolites that may be used as a biomarker for exogenous 
administration. 
Because of the complex nature of feces and urine, appropriate sample preparation procedures 
were required, but in terms of the metabolomic approach to be kept as generic as possible. To 
this extent, Placket Burman designs were successfully applied to develop two different 
sample preparations protocols each based on a two-step liquid-liquid extraction with tert-
butyl methylether. For feces, this was followed by a solid phase extraction with C18 
cartridges. Metabolomic profiling was performed using ultra-high-performance liquid 
chromatography coupled to full scan high resolution Orbitrap mass spectrometry by a 
combination of targeted and untargeted analysis. The targeted analyses were successfully 
validated according to CD 2002/657. Decision limits and detection capabilities for 
prednisolone, prednisone and methylprednisolone ranged in urine, respectively, from 0.1 to 
0.5 µg L-1 and from 0.3-0.8 µg L-1. For the natural glucocorticoids limits of detection and 
limits of quantification for dihydrocortisone, cortisol and cortisone ranged, respectively, from 
0.1 to 0.2 µg L-1 and from 0.3 to 0.8 µg L-1. In feces similar results were obtained. 
The applicability of the analytical methods for untargeted metabolomic profiling was 
demonstrated by using ToXID, SieveTM (Thermo Fisher Scientific) and SimcaTM (Unimetrics) 
software, enabling an efficient screening of the full scan data. A first screening was conducted 
on urine and feces samples collected from 2 cows and 2 calves after oral administration with 
prednisolone (1 mg kg-1 BW). Several prednisolone metabolites were identified, including 
20β-dihydroprednisolone and 20α-dihydroprednisolone. The potential of these metabolites as 
a biomarker for illegal administration as opposed to endogenous formation will be further 
investigated in a larger in vivo design. 
